Skip to main content

Advertisement

SpringerLink
Log in

Primary hormone therapy for locally advanced prostate cancer

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Locally advanced prostate cancer is a treatment dilemma. As with prostate cancer in general, there is no clear evidence that aggressive intervention (ie, surgery or radiation) is superior to noninvasive interventions (eg, delayed treatment or androgen ablation). Because patients with locally advanced prostate cancer have a high risk of local and systemic recurrence, there is some argument to proceed with androgen ablation as the sole modality of treatment. The data using this approach are limited, but an understanding of the degree and duration of response is helpful in selecting patients for primary androgen ablation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Walsh PC, DeWeese TL, Eisenberger MA: A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 2001, 166:508–516.

    Article  PubMed  CAS  Google Scholar 

  2. Whitmore WF: Hormone therapy in prostatic cancer. Am J Med 1956, 21:697–712.

    Article  PubMed  Google Scholar 

  3. Huggins C, Hodges CV: Studies on prostate cancer: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:292–297.

    Google Scholar 

  4. D’Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969–974.

    Article  PubMed  CAS  Google Scholar 

  5. Zelefsky MJ, Fuks Z, Hunt M, et al.: High-dose radiation delivered by intensity-modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166:876–881.

    Article  PubMed  CAS  Google Scholar 

  6. Nesbit RM, Baum WC: Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. J Am Med Assoc 1950, 143:1317–1320.

    PubMed  CAS  Google Scholar 

  7. Emmett JL, Greene LF, Papantoniou A: Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies. J Urol 1960, 83:471–484.

    PubMed  CAS  Google Scholar 

  8. Lepor H, Ross A, Walsh P: The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982, 128:335–340.

    PubMed  CAS  Google Scholar 

  9. Byar DP: Proceedings: the Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 1973, 32:1126–1130.

    Article  PubMed  CAS  Google Scholar 

  10. Blackard CE, Byar DP, Jordon WP: Orchiectomy for advanced prostatic carcinoma: a re-evaluation. Urology 1973, 1:553.

    Article  PubMed  CAS  Google Scholar 

  11. Byar DP, Corle DK: Hormone therapy for prostate cancer: results of the Veterans Administration Urological Research Group studies. NCI Monogr 1988, 7:165–170. Classic randomized study on androgen ablation.

    PubMed  Google Scholar 

  12. Anonymous: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997, 79:235–246. Classic randomized study on androgen ablation.

    Google Scholar 

  13. Kirk D: Timing and choice of androgen ablation. Prostate Cancer Prostatic Dis 2004, 7:217–222.

    Article  PubMed  CAS  Google Scholar 

  14. Smith PH, Suciu S, Robinson MR, et al.: A comparison of the effect of diethylstilbestrol with low-dose estramustine phosphate in the treatment of advanced prostate cancer: final analysis of a phase-III trial of the European Organization for Research on Treatment of Cancer. J Urol 1986, 136:619–623.

    PubMed  CAS  Google Scholar 

  15. Pavone M, de Voogt HJ, Barasolo VE, et al.: Comparison of diethylstilbestrol, cyproterone acetate, and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase-III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986, 136:624–631.

    Google Scholar 

  16. Oefelein MG, Ricchiuti VS, Conrad PW, et al.: Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology 2002, 60:120–124.

    Article  PubMed  Google Scholar 

  17. Fowler JE, Bigler SA, White PC, Duncanc WL: Hormone therapy for locally advanced prostate cancer. J Urol 2002, 168:546–549.

    Article  PubMed  CAS  Google Scholar 

  18. Dupont A, Cusan L, Gomez JL, et al.: Combination therapy with flutamide and the LHRH agonist [D-trp6, des-Gly-NH2 10] LHRH ethylamide in stage-C prostate cancer. Br J Urol 1993, 72:629–634.

    Article  PubMed  CAS  Google Scholar 

  19. Hachiya T, Koichiro A, Saito S, et al.: A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and northeastern Japan. BJU Int 2005, 95:534–540.

    Article  PubMed  Google Scholar 

  20. Homma Y, Akaza H, Okada K, et al.: Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer. Int J Urol 2004, 11:218–224.

    Article  PubMed  Google Scholar 

  21. Studer UE, Whelan P, Albrecht W, et al.: Immediate versus deferred androgen deprivation in patients with asymptomatic prostate cancer T0-4 N0-2 M0 not suitable for local definitive treatment [Abstract 1659]. J Urol 2005, 173:450.

    Article  Google Scholar 

  22. Studer UE, Hauri D, Hanselmann S, et al.: Immediate versus deferred hormonal therapy for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004, 22:4109–4118 [Erratum in J Clin Oncol 2005, 23:936].

    Article  PubMed  Google Scholar 

  23. Morote J, Trilla E, Esquena S, et al.: Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Can 2004, 108:877–881.

    Article  CAS  Google Scholar 

  24. Gleave ME, Goldenberg SL, Jones EC, et al.: Biochemical and pathological effects of 8 months of neoadjuvant withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996, 155:213–219.

    Article  PubMed  CAS  Google Scholar 

  25. Gleave ME, Goldenberg SL, Chin JL, et al.: Randomized comparative study of 3-versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001, 166:500–507.

    Article  PubMed  CAS  Google Scholar 

  26. Soloway MS, Sharifi R, Wajsman Z, et al.: Randomized, prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage-B2 (T2bNxM0) prostate cancer: the Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995, 154:424–428.

    Article  PubMed  CAS  Google Scholar 

  27. Klein EA: Hormone therapy for prostate cancer: a topical perspective. Urology 1996, 47(suppl 1A):3–12.

    Article  PubMed  CAS  Google Scholar 

  28. Sogani PC, Vagaiwala MR, Whitmore WF: Experience with flutamide in patients with advanced prostate cancer without prior endocrine therapy. Cancer 1984, 54:744–750.

    Article  PubMed  CAS  Google Scholar 

  29. Blackledge GR: High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology 1996, 47:44–47.

    Article  PubMed  CAS  Google Scholar 

  30. Mayer FJ, Crawford ED: The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy. Urol Clin North Am 1994, 21:707–715.

    PubMed  CAS  Google Scholar 

  31. Boccardo F, Rubagotti A, Barichello M, et al.: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999, 17:2027–2038.

    PubMed  CAS  Google Scholar 

  32. Iversen P, Tyrrell CJ, Kaisary AV, et al.: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000, 164:1579–1582.

    Article  PubMed  CAS  Google Scholar 

  33. Iversen P, Johansson JE, Lodding P, et al.: Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004, 172:1871–1876.

    Article  PubMed  Google Scholar 

  34. Wirth MP, See WA, McLeod DG, et al.: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median follow up of 5.4 years. J Urol 2004, 172:1865–1870.

    Article  PubMed  CAS  Google Scholar 

  35. Kaisary AV: Compliance with hormonal treatment for prostate cancer. Br J Hosp Med 1996, 55:359–366.

    PubMed  CAS  Google Scholar 

  36. http://www.hsa.gov.sg/docs/safetyalert_bicalutamide_ Nov03.pdf. Accessed January 27, 2006.

  37. Lawton CA, Winter K, Murray K, et al.: Updated results of the phase-III Radiation Therapy Oncology Group (RTOG) Trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Biol Phys 2001, 49:937–946.

    Article  CAS  Google Scholar 

  38. Bolla M, Collette L, Blank L, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): phase-III randomized trial. Lancet 2002, 360:103–106.

    Article  PubMed  CAS  Google Scholar 

  39. Hanks G, Pajak TF, Porter A, et al.: Phase-III trial of longterm adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02. J Clin Oncol 2003, 21:3972–3978.

    Article  PubMed  CAS  Google Scholar 

  40. Herr HW, O’Sullivan M: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000, 163:1743–1746.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Health Science Center, San Antonio, 7703 Floyd Curl Drive, MC 7889, 78229, San Antonio, TX, USA

    Gregory P. Swanson MD

Authors
  1. Gregory P. Swanson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory P. Swanson MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swanson, G.P. Primary hormone therapy for locally advanced prostate cancer. Curr Urol Rep 7, 225–232 (2006). https://doi.org/10.1007/s11934-006-0025-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-006-0025-x

Keywords

Search

Navigation